MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597277 | Name: Polyglutamine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Polyglutamine is a portion of a protein consisting of a sequence of several glutamine units. A tract typically consists of about 10 to a few hundred such units. A multitude of genes, in various eukaryotic species (including humans), contain a number of repetitions of the nucleotide triplet CAG or CAA. When the gene is translated into a protein, each of these triplets gives rise to a glutamine unit, resulting in a polyglutamine tract. Different alleles of such a gene often have different numbers of triplets since the highly repetitive sequence is prone to contraction and expansion.

Chemical Structure

Polyglutamine
Polyglutamine
CAS#26700-71-0

Theoretical Analysis

MedKoo Cat#: 597277

Name: Polyglutamine

CAS#: 26700-71-0

Chemical Formula: C5H10N2O3

Exact Mass: 146.0691

Molecular Weight: 146.14

Elemental Analysis: C, 41.09; H, 6.90; N, 19.17; O, 32.84

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Polyglutamine; Poly(glutamine);
IUPAC/Chemical Name
L-glutamine
InChi Key
ZDXPYRJPNDTMRX-VKHMYHEASA-N
InChi Code
InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1
SMILES Code
NC(CC[C@H](N)C(O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 146.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chen CM, Chen WL, Hung CT, Lin TH, Chao CY, Lin CH, Wu YR, Chang KH, Yao CF, Lee-Chen GJ, Su MT, Hsieh-Li HM. The indole compound NC009-1 inhibits aggregation and promotes neurite outgrowth through enhancement of HSPB1 in SCA17 cells and ameliorates the behavioral deficits in SCA17 mice. Neurotoxicology. 2018 Jun 21;67:259-269. doi: 10.1016/j.neuro.2018.06.009. [Epub ahead of print] PubMed PMID: 29936316. 2: Zhao Y, Zurawel AA, Jenkins NP, Duennwald ML, Cheng C, Kettenbach AN, Supattapone S. Comparative Analysis of Mutant Huntingtin Binding Partners in Yeast Species. Sci Rep. 2018 Jun 22;8(1):9554. doi: 10.1038/s41598-018-27900-5. PubMed PMID: 29934597. 3: Toonen LJA, Overzier M, Evers MM, Leon LG, van der Zeeuw SAJ, Mei H, Kielbasa SM, Goeman JJ, Hettne KM, Magnusson OT, Poirel M, Seyer A, 't Hoen PAC, van Roon-Mom WMC. Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model. Mol Neurodegener. 2018 Jun 22;13(1):31. doi: 10.1186/s13024-018-0261-9. PubMed PMID: 29929540. 4: Marco S, Murillo A, Pérez-Otaño I. RNAi-Based GluN3A Silencing Prevents and Reverses Disease Phenotypes Induced by Mutant huntingtin. Mol Ther. 2018 Jun 15. pii: S1525-0016(18)30216-8. doi: 10.1016/j.ymthe.2018.05.013. [Epub ahead of print] PubMed PMID: 29914757. 5: Ko J, Isas JM, Sabbaugh A, Yoo JH, Pandey NK, Chongtham A, Ladinsky M, Wu WL, Rohweder H, Weiss A, Macdonald D, Munoz-Sanjuan I, Langen R, Patterson PH, Khoshnan A. Identification of distinct conformations associated with monomers and fibril assemblies of mutant huntingtin. Hum Mol Genet. 2018 Apr 18. doi: 10.1093/hmg/ddy141. [Epub ahead of print] PubMed PMID: 29912367; PubMed Central PMCID: PMC6005051. 6: McLoughlin HS, Moore LR, Chopra R, Komlo R, McKenzie M, Blumenstein KG, Zhao H, Kordasiewicz HB, Shakkottai VG, Paulson HL. Oligonucleotide therapy mitigates disease in Spinocerebellar Ataxia Type 3 mice. Ann Neurol. 2018 Jun 16. doi: 10.1002/ana.25264. [Epub ahead of print] PubMed PMID: 29908063. 7: Tang BL. Unconventional Secretion and Intercellular Transfer of Mutant Huntingtin. Cells. 2018 Jun 14;7(6). pii: E59. doi: 10.3390/cells7060059. Review. PubMed PMID: 29904030. 8: Liu SY, Yu XL, Zhu J, Liu XM, Zhang Y, Dong QX, Ma S, Liu RT. Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6/2 mouse model of Huntington's disease by decreasing mutant huntingtin protein level and normalizing NF-κB signaling pathway. Brain Res. 2018 Jun 11. pii: S0006-8993(18)30336-6. doi: 10.1016/j.brainres.2018.06.009. [Epub ahead of print] PubMed PMID: 29902468. 9: Xu Y, Halievski K, Katsuno M, Adachi H, Sobue G, Breedlove SM, Jordan CL. Pre-clinical symptoms of SBMA may not be androgen-dependent: Implications from two SBMA mouse models. Hum Mol Genet. 2018 Apr 20. doi: 10.1093/hmg/ddy142. [Epub ahead of print] PubMed PMID: 29897452. 10: Pan Y, Zhu Y, Yang W, Tycksen E, Liu S, Palucki J, Zhu L, Sasaki Y, Sharma MK, Kim AH, Zhang B, Yano H. The role of Twist1 in mutant huntingtin-induced transcriptional alterations and neurotoxicity. J Biol Chem. 2018 Jun 11. pii: jbc.RA117.001211. doi: 10.1074/jbc.RA117.001211. [Epub ahead of print] PubMed PMID: 29891550. 11: Bryan AC, Zhang J, Guo J, Ranjan P, Singan V, Barry K, Schmutz J, Weighill D, Jacobson D, Jawdy S, Tuskan GA, Chen JG, Muchero W. A Variable Polyglutamine Repeat Affects Subcellular Localization and Regulatory Activity of a Populus ANGUSTIFOLIA Protein. G3 (Bethesda). 2018 Jun 8. pii: g3.200188.2018. doi: 10.1534/g3.118.200188. [Epub ahead of print] PubMed PMID: 29884614. 12: Raj K, Sarkar S. Tissue-Specific Upregulation of Drosophila Insulin Receptor (InR) Mitigates Poly(Q)-Mediated Neurotoxicity by Restoration of Cellular Transcription Machinery. Mol Neurobiol. 2018 Jun 7. doi: 10.1007/s12035-018-1160-3. [Epub ahead of print] PubMed PMID: 29881950. 13: Torres-Ramos Y, Montoya-Estrada A, Cisneros B, Tercero-Pérez K, León-Reyes G, Leyva-García N, Hernández-Hernández O, Magaña JJ. Oxidative Stress in Spinocerebellar Ataxia Type 7 Is Associated with Disease Severity. Cerebellum. 2018 Jun 6. doi: 10.1007/s12311-018-0947-0. [Epub ahead of print] PubMed PMID: 29876803. 14: Egorova PA, Gavrilova AV, Bezprozvanny IB. In Vivo Analysis of the Climbing Fiber-Purkinje Cell Circuit in SCA2-58Q Transgenic Mouse Model. Cerebellum. 2018 Jun 6. doi: 10.1007/s12311-018-0951-4. [Epub ahead of print] PubMed PMID: 29876801. 15: Fujikake N, Shin M, Shimizu S. Association Between Autophagy and Neurodegenerative Diseases. Front Neurosci. 2018 May 22;12:255. doi: 10.3389/fnins.2018.00255. eCollection 2018. Review. PubMed PMID: 29872373; PubMed Central PMCID: PMC5972210. 16: Vidinská D, Vochozková P, Šmatlíková P, Ardan T, Klíma J, Juhás Š, Juhásová J, Bohuslavová B, Baxa M, Valeková I, Motlík J, Ellederová Z. Gradual Phenotype Development in Huntington Disease Transgenic Minipig Model at 24 Months of Age. Neurodegener Dis. 2018 Jun 5;18(2-3):107-119. doi: 10.1159/000488592. [Epub ahead of print] PubMed PMID: 29870995. 17: Xiang C, Zhang S, Dong X, Ma S, Cong S. Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies. Front Mol Neurosci. 2018 May 15;11:153. doi: 10.3389/fnmol.2018.00153. eCollection 2018. Review. PubMed PMID: 29867345; PubMed Central PMCID: PMC5962650. 18: Romo L, Mohn ES, Aronin N. A Fresh Look at Huntingtin mRNA Processing in Huntington's Disease. J Huntingtons Dis. 2018;7(2):101-108. doi: 10.3233/JHD-180292. PubMed PMID: 29865084; PubMed Central PMCID: PMC6004895. 19: Takeuchi T. Non-cell Autonomous Maintenance of Proteostasis by Molecular Chaperones and Its Molecular Mechanism. Biol Pharm Bull. 2018;41(6):843-849. doi: 10.1248/bpb.b18-00141. PubMed PMID: 29863073. 20: Vishwakarma P, Muthuswamy S, Agarwal S. Current molecular insight to reveal the dynamics of CAG repeating units in spinocerebellar ataxia. Intractable Rare Dis Res. 2018 May;7(2):79-86. doi: 10.5582/irdr.2018.01039. Review. PubMed PMID: 29862148; PubMed Central PMCID: PMC5982628.